
Results
7
Companies which are more than 50% undervalued based on analyst price target.
7 companies
Caliway Biopharmaceuticals
Market Cap: NT$159.4b
Engages in the development of drugs for aesthetic medicine and chronic inflammation.
6919
NT$104.50
7D
-3.2%
1Y
-40.3%
Lotus Pharmaceutical
Market Cap: NT$48.2b
Engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally.
1795
NT$184.50
7D
-2.4%
1Y
-4.9%
Oneness Biotech
Market Cap: NT$22.5b
Engages in the research, development, and sale of new drugs, pharmaceuticals, and health products in Taiwan.
4743
NT$47.30
7D
0%
1Y
-32.2%
TaiMed Biologics
Market Cap: NT$16.8b
A biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases.
4147
NT$63.00
7D
-0.8%
1Y
-19.4%
Medigen Vaccine Biologics
Market Cap: NT$16.6b
A biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan.
6547
NT$52.30
7D
0.6%
1Y
33.2%
EirGenix
Market Cap: NT$14.8b
Operates as a contract development and manufacturing company in Taiwan and internationally.
6589
NT$48.70
7D
-7.4%
1Y
-19.5%
Foresee Pharmaceuticals
Market Cap: NT$12.5b
Operates as biopharmaceutical company in the United States, China, and Europe.
6576
NT$78.90
7D
-0.8%
1Y
0.1%